BioVie Inc.
BIVI
BIVI
Nasdaq
Health Technology
Biotechnology
1.28
USD+0.02
+1.59%
Closed: 10-22 20:00 (UTC+0)
1.23
USD-0.0499
-3.90%
After Hours: 10-23 00:00 (UTC+0)
BIVI Key Statistics
High
1.29
Open
1.24
Volume
101.04K
Low
1.22
Prev. Close
1.26
Trading Value
125.85K
52-Week High
3.79
Relative Volume
0.551
Amplitude (%)
5.95%
52-Week Low
0.82
Turnover Rate
1.16%
Market Cap
11.11M
P/E Ratio (TTM)
--
P/E Ratio (Annual)
--
P/B Ratio
1.08
P/S Ratio
--
Earnings Per Share (EPS)
-3.197
Dividend (TTM)
0
Dividend Yield
0.00%
Shares Outstanding
8.68M
Currency Unit
USD
BIVI Price Performance
7 day
30 day
90 day
180 day
Year to date
1 Year
BIVI Money Flow Distribution
BIVI Daily Short Sale Volume
BIVI Short Interest History
BIVI Stock Snapshot
As of 2026-10-23, the BioVie Inc. (BIVI) stock price today is 1.28. Based on this price, the company has a market capitalization of $11.11M, with a P/E ratio of --.
On 2026-10-23, BIVI traded between 1.22 and 1.29. Today’s stock price is 4.92% above the daily low and 0.78% below the daily high, placing BIVI near the upper end of its most recent trading range.
Trading volume currently stands at 101.04K, compared with an average daily volume of 183.42K. This suggests that trading activity is below its usual level than usual.
Over the past year, BioVie Inc. shares have traded between 0.82 and 3.79. At today’s price, BIVI is 56.10% above its 52-week low and 66.23% below its 52-week high.
BIVI Related News
About BIVI
Company Name
BioVie Inc.
Sector
Health Technology
Industry
Biotechnology
Exchanges
Nasdaq
Number of Employees
13
Lot Size
100
Official Website
Currency Unit
USD
BioVie Inc. (BIVI) is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism. The company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease.
BIVI FAQ
© 2026 CoinGlass, all rights reserved
